Abstracts tagged "chondroitin"

Abstract Number: 1361 • 2018 ACR/ARHP Annual Meeting
Predictive Modeling of Therapeutic Response in Knee Osteoarthritis
Valentina Calamia¹, Florencia Picchi¹, Ignacio Rego-Pérez², Maria Camacho¹, Lucia González¹, Patricia Fernández³, Marta Herrero⁴, Helena Martinez⁴, Josep Vergés⁵, Cristina Ruiz-Romero⁶ and Francisco J Blanco⁷, ¹Rheumatology Research Group, Proteomics Unit-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, ²Rheumatology Research Group, Genomic Unit, INIBIC-CHUAC, A Coruña, Spain, ³Proteomics group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, La Coruña, Spain, ⁴Clinical R&D Area, Bioiberica, SAU, Barcelona, Spain, ⁵Osteoarthritis Foundation International, Barcelona, Spain, ⁶Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ⁷Rheumatology Divison, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain
Background/Purpose: Phenotype identification in knee osteoarthritis (KOA) population could be useful for predicting drug response, allowing personalized interventions. In order to optimize therapeutic outcome in…
Abstract Number: 1203 • 2017 ACR/ARHP Annual Meeting
Differences in Serum Protein Biomarkers between Combined Glucosamine and Chondroitin Versus Celecoxib Treatment in a Randomized, Double-Blind Trial in Osteoarthritis Patients
Sandi L Navarro¹, Marta Herrero², Helena Martinez², Jon Ladd¹, Yuzheng Zhang¹, Edward Lo¹, David Shelley¹, Timothy W Randolph¹, Yvonne Schwarz¹, Johanna W Lampe¹ and Paul D Lampe¹, ¹Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, ²Clinical R&D Area, Bioiberica, SAU, Barcelona, Spain
Background/Purpose: Non-steroidal anti-inflammatory drugs, e.g., celecoxib, are commonly used for inflammatory conditions, including osteoarthritis (OA), but are associated with adverse effects. Combined glucosamine hydrochloride plus…
Abstract Number: 1208 • 2017 ACR/ARHP Annual Meeting
Levels of Serum Biomarkers from a Two-Year Multicentre Trial Are Associated with Treatment Response on Knee Osteoarthritis Cartilage Loss As Assessed By MRI: An Exploratory Study
Johanne Martel-Pelletier¹, Jean-Pierre Raynauld¹, François Mineau¹, François Abram², Patrice Paiement³, Philippe Delorme³ and Jean-Pierre Pelletier¹, ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²Medical Imaging Research & Development, ArthroLab Inc., Montreal, QC, Canada, ³ArthroLab Inc., Montreal, QC, Canada
Background/Purpose: There is an obvious need to identify biomarkers that could predict patient response to an osteoarthritis (OA) treatment. This post hoc study explored in…
Abstract Number: 1190 • 2017 ACR/ARHP Annual Meeting
Orosomucoid 2 Serves As Predictor of Therapeutic Response in Osteoarthritis Patients Treated with Chondroitin Sulfate/Glucosamine Hydrochloride
Valentina Calamia¹, M Camacho¹, Ignacio Rego-Pérez¹, L González¹, P Fernández-Puente¹, F Picchi¹, Marta Herrero², Helena Martinez², C Ruiz-Romero¹ and Francisco J Blanco^3,4, ¹Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain, ²Clinical R&D Area, Bioiberica, SAU, Barcelona, Spain, ³RIER-RED de Inflamación y Enfermedades Reumáticas, INIBIC-CHUAC, A Coruña, Spain, A Coruña, Spain, ⁴Rheumatology Division, ProteoRed/ISCIII, Proteomics Group, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain
Orosomucoid 2 Serves as Predictor of Therapeutic Response in Osteoarthritis Patients Treated with Chondroitin Sulfate/Glucosamine HydrochlorideV. Calamia, M. Camacho, I. Rego-PŽrez, L. Gonz‡lez, P. Fern‡ndez-Puente,…
Abstract Number: 2231 • 2014 ACR/ARHP Annual Meeting
Combined Chondroitin Sulfate and Glucosamine Is Comparable to Celecoxib for Painful Knee Osteoarthritis. Results from a Multicenter, Randomized, Double-Blind, PHASE IV NON-Inferiority TRIAL
Marc Hochberg¹, Johanne Martel-Pelletier², Jordi Monfort³, Ingrid Moller⁴, Juan Ramon Castillo⁵, Nigel K. Arden^6,7,8, Francis Berenbaum^9,10, Jean-Pierre Pelletier¹¹, Francisco J. Blanco¹², Philip G. Conaghan¹³, Yves Henrotin^14,15, Thomas Pap¹⁶, Pascal Richette^17,18,19, Allen Sawitzke²⁰, Patrick du Souich²¹ and Moves Investigation Group²², ¹University of Maryland School of Medicine, Baltimore, MD, ²Osteoarthritis Research Unit CR-CHUM, Notre-Dame Hospital 1560 Sherbrooke St East, Montreal, QC, Canada, ³Department of Rheumatology, Grup de recerca cel•lular en inflamació i cartílag. IMIM (Institut de Recerca Hospital del Mar), Barcelona, Spain, ⁴Instituto Poal, Barcelona, Spain, ⁵Head of Clinical Pharmacology Unit Hospital Universitario Virgen del Rocío, Sevilla, Spain;, Sevilla, Spain, ⁶NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, ⁷Arthritis Research UK (ARUK), Center for Sports, Exercise and Osteoarthritis, University of Oxford, Nuffield Orthopaedic Centre, Oxford, United Kingdom, ⁸MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ⁹Sorbonne University, INSERM UMR S938, UPMC, University of Paris 06, DHU i2B, Paris, France, ¹⁰Department of Rheumatology, Assistance Publique – Hôpitaux de Paris, Saint-Antoine Hospital, Paris, France, ¹¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, Canada, ¹²Rheumatology Service, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ¹³University of Leeds, Leeds, United Kingdom, ¹⁴Physical Therapy and Rehabilitation Department, Princess Paola Hospital, Marche-en-Famenne, Belgium, ¹⁵Bone and Cartilage Research Unit, Arthropôle Liège, University of Liège, Institute of Pathology, CHU Sart-Tilman, Liege, Belgium, ¹⁶Institute of Experimental Muskuloskeletal Medicine University Hospital Münster, Münster, Germany, ¹⁷Université Paris Diderot, UFR médicale, Paris, France, ¹⁸INSERM 1132, Université Paris-Diderot, Hôpital Lariboisière, Paris, France, ¹⁹2 Rue Ambroise Pare, Hopital Lariboisiere, Paris, France, ²⁰Rheumatology, University of Utah Medical Center, Salt Lake City, UT, ²¹Department of Pharmacology, Faculty of Medicine, University of Montreal, Montreal, QC, Canada, ²²Spain, Germany, France and Poland, Barcelona, Spain
Background/Purpose The Multicentre Osteoarthritis interVEntion trial with Sysadoa (MOVES) compared efficacy and safety of Chondroitin sulfate (CS) and Glucosamine Hydrochloride (GH) with that of Celecoxib…
Abstract Number: 2250 • 2014 ACR/ARHP Annual Meeting
The Effects of Treatment on Disease Symptoms and Progression of Structural Changes in Knee Osteoarthritis Participants from the Osteoarthritis Initiative Progression Cohort
Jean-Pierre Pelletier¹, Camille Roubille¹, François Abram², Marc Dorais³, Philippe Delorme¹, Jean-Pierre Raynauld¹ and Johanne Martel-Pelletier¹, ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²Medical Imaging Research & Development, ArthroLab Inc., Montreal, QC, Canada, ³StatSciences Inc., Notre-Dame de l’Île-Perrot, QC, Canada
Background/Purpose: In the perspective of personalized management of osteoarthritis (OA), a clinically relevant concern is the impact of meniscal extrusion on response to treatment. This study evaluated the role…
Abstract Number: 169 • 2013 ACR/ARHP Annual Meeting
Effects Of Chondroitin Sulfate On The Gene Expression Profile In Interleukin-1β Stimulated Synovial Fibroblast Cells Cultures
Cécile Lambert¹, Jean-Emile Dubuc², Eulalia Montell³, Josep Verges³ and Yves Henrotin¹, ¹University of Liège, Bone and Cartilage Research Unit, Liège, Belgium, ²Clinical University Saint Luc, Orthopaedic Department, Bruxelles, Belgium, ³Pre-Clinical R&D Area, Pharmascience Division, BIOIBERICA S.A., Barcelona, Spain
Background/Purpose: Chondroitin sulfate (CS) is one the most used molecules in the management of OA. Its mechanism of action remains to be detailed. In this…
Abstract Number: 171 • 2013 ACR/ARHP Annual Meeting
Effects Of Chondroitin Sulfate On The Gene Expression Profile In The Inflamed Synovial Membrane
Cécile Lambert¹, Jean-Emile Dubuc², Eulalia Montell³, Josep Verges³ and Yves Henrotin¹, ¹University of Liège, Bone and Cartilage Research Unit, Liège, Belgium, ²Clinical University Saint Luc, Orthopaedic Department, Bruxelles, Belgium, ³Pre-Clinical R&D Area, Pharmascience Division, BIOIBERICA S.A., Barcelona, Spain
Background/Purpose: Chondroitin sulfate (CS) is one the most used molecules in the management of OA. Its mechanism of action remains to be detailed. The aim…
Abstract Number: 2145 • 2013 ACR/ARHP Annual Meeting
Impact On Cartilage Volume Changes Over Time Of Conventional Treatment and Of Glucosamine and Chondroitin Sulfate In Knee Osteoarthritis Patients: Data From The Osteoarthritis Initiative Cohort
Johanne Martel-Pelletier¹, Camille Roubille¹, Jean-Pierre Raynauld¹, François Abram², Pierre Dodin³, Marc Dorais⁴, Philippe Delorme¹ and Jean-Pierre Pelletier¹, ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²Medical Imaging Research & Development, ArthroLab Inc., Montreal, QC, Canada, ³Imaging Research & Development, ArthroLab Inc., Montreal, QC, Canada, ⁴StatSciences Inc., Notre-Dame de l’Île Perrot, QC, Canada
Background/Purpose: To explore, using data from participants enrolled in the progression cohort of the Osteoarthritis Initiative (OAI), the effects of conventional knee osteoarthritis (OA) pharmacological…
Abstract Number: 2146 • 2013 ACR/ARHP Annual Meeting
Effects Of Chondroitin Sulfate On Brain Response To Painful Stimulation In Knee Osteoarthritis Patients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Jordi Monfort¹, Jesús Pujol², O Contreras-Rodriguez², Jone Llorente-Onaindia², M López-Solà², Laura Blanco-Hinojo², J Deus², H Ortiz², Francisco Montañés³, M Campillo², Pere Benito², Laura Sánchez⁴, Marta Herrero⁵ and Josep Vergés⁶, ¹Reumatologia, Hospital del Mar, Barcelona, Spain, ²Hospital del Mar, Barcelona, Spain, ³Rhaumatology, Hospital del Mar, Barcelona, Spain, ⁴Bioiberica, Barcelona, Spain, ⁵Pharmascience Division, Bioiberica S.A., Barcelona, Spain, ⁶Pre-Clinical R&D Area, Pharmascience Division, BIOIBERICA S.A., Barcelona, Spain
Background/Purpose: Knee osteoarthritis (OA) is a degenerative joint disease causing symptoms in 12% of people over the age of 65 . A variety of treatments…
Abstract Number: 2113 • 2013 ACR/ARHP Annual Meeting
Glucosamine–Chondroitin Sulfate Reduces Pain, Disability and Non-Steroidal Anti-Inflammatory Drug consumption In Patients With Chronic Low Back Pain: A Large, Community-Based, Pilot, Open Prospective Study
Gurkirpal Singh^1,2, Liudmila Alekseeva³, Valeriy Alekseev⁴ and Evgeny Nasonov⁵, ¹ICORE, Woodside, CA, ²Gastroenterology/Hepatology, Stanford University School of Medicine, Palo Alto, CA, ³State Institute of Rheumatology of Russian Academy of Medical Sciences, Moscow, Russia, ⁴Department of Nervous Diseases, First Moscow State Medical University, Moscow, Russia, ⁵State NII of Rheumatology of Russian Academy of Sciences, Moscow, Russia
Background/Purpose: The Global Burden of Diseases, Injuries, and Risk Factors Study 2010 identified low back pain as the leading cause of Years Lived with Disability…
Abstract Number: 858 • 2013 ACR/ARHP Annual Meeting
Monosodium Urate Crystal Induced Macrophage Inflammation Is Attenuated By Chondroitin Sulfate: Pre-Clinical Model For Gout Prophylaxis?
Eric W. Orlowsky¹, Thomas V. Stabler², Eulalia Montell³, Josep Verges³ and Virginia B. Kraus², ¹Divsion of Rheumatology, Dept of Internal Medicine, Duke University Medical Center, Durham, NC, ²Medicine/Rheumatology, Duke University Medical Center, Durham, NC, ³Pre-Clinical R&D Area, Pharma Science Division, Bioibérica, Barcelona, Spain
Background/Purpose: Gout is one of the most common forms of inflammatory arthritis and is characterized by acute episodes of joint pain. Monosodium urate (MSU) crystals…
Abstract Number: 1124 • 2012 ACR/ARHP Annual Meeting
Total Knee Replacement As an Osteoarthritis Study Outcome: Predictors Derived From Long-Term Observation Following a Randomized Clinical Trial
Jean-Pierre Raynauld¹, Johanne Martel-Pelletier¹, Marc Dorais², Boulos Haraoui¹, Denis Choquette¹, François Abram³, André Beaulieu⁴, Louis Bessette⁵, Frédéric Morin⁶, Lukas M. Wildi¹ and Jean Pierre Pelletier⁷, ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²StatSciences Inc., Notre-Dame de l’Île Perrot, QC, Canada, ³Medical Imaging Research & Development, ArthroLab Inc., Montreal, QC, Canada, ⁴Faculty of Medicine, Laval University, Quebec, QC, Canada, ⁵Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ⁶Centre de Recherche Musculo-squelettique, Trois-Rivières, QC, Canada, ⁷Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, Canada
Background/Purpose: Using data from a 4-year follow-up of knee OA patients who formerly received treatment with chondroitin sulfate (CS) within a 6-month clinical trial, we…
Abstract Number: 1135 • 2012 ACR/ARHP Annual Meeting
Combined Glucosamine and Chondroitin Sulfate, Once of Three Times Daily, Provide Clinically Relevant Analgesia in Knee Osteoarthritis
Jose R. Provenza¹, Samuel K. Shinjo², Joyce M. Silva³, Carla RGS. Peron⁴ and Francisco AC Rocha⁵, ¹Rheumatology, Pontifícia Universidade Católica de Campinas, Campinas, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ³Clinical Research, Sao Paulo, Brazil, ⁴Clinical Research, Laboratórios Aché Ltda, Sao Paulo, Brazil, ⁵Rheumatology, Brazilian Registry of Spondyloarthritis, São Paulo, Brazil
Background/Purpose: The analgesic efficacy of combined glucosamine and chondroitin sulfate (CS) in knee osteoarthritis (OA) remains controversial. Criticism to previous studies includes small sample size,…
Abstract Number: 1101 • 2012 ACR/ARHP Annual Meeting
Condroitin Sulfate Decreases Chemokine Levels and Synovitis in knee osteoarthritis Patients
Jordi Monfort¹, Paula Escudero², Cristobal Orellana³, Laura Piqueras⁴, Laura Tio⁵, Francisco Montañés⁶, Natalia García⁷, Chantal Company², Pere Benito⁸ and Maria Jesús Sanz², ¹Reumatologia, Hospital del Mar, Barcelona, Spain, ²Pharmacology, Universitary Clinic Hospital Research Foundation-INCLIVA, University of Valencia, Valencia, Spain, ³Rheumatology, Corporació Sanitaria Parc Taulí, Sabadell, Spain, ⁴University Clinic Hospital Research Foundation-INCLIVA, University of Valencia, Valencia, Spain, ⁵U.R. Inflamació cel·lular i cartílag, GRICIC. FIMIM, Barcelona, Spain, ⁶Rhaumatology, Hospital del Mar, Barcelona, Spain, ⁷GRICIC. FIMIM, Barcelona, Spain, ⁸Hospital del Mar, Barcelona, Spain
Background/Purpose: Synovitis is one of the major signs of structure damage in osteoarthritis (OA) progression. Chondroitin sulfate (CS) is an effective drug in the treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].